China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market far larger than the US, and one that pharmaceutical groups are rushing to dominate.
manbetx3.0 的肥胖危机是一个巨大的盈利机会。超过一半的manbetx3.0 成年人超重或肥胖——预计到2030年这一比例将达到三分之二。这相当于近9亿人口，这是一个比美国大得多的市场，也是制药集团争相希望主导的市场。
您已阅读11%（377字），剩余89%（2979字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。